Information Provided By: 
Fly News Breaks for May 15, 2017
CORT
May 15, 2017 | 06:52 EDT
In a research note titled "How Broad Can Effects of Excessive Stress Hormone Be? Don't Borrow Shares...," Piper Jaffray analyst Charles Duncan says he likes the setup here for Corcept Therapeutics. After hosting investor meetings with management, the analyst has confidence in his growth projections for the company's Cushing's franchise. He believes revenue growth for the unit is just beginning and reiterates an Overweight rating on Corcept with an $18 price target.
News For CORT From the Last 2 Days
There are no results for your query CORT
